LSTM Home > LSTM Research > LSTM Online Archive

Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax

Milligan, Rachael, Daher, Andre, Villanueva, Gemma, Bergman, Hanna and Graves, Patricia M (2020) 'Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax'. The Cochrane Database of Systematic Reviews, Vol 8, CD012656.

Milligan_et_al-2020-Cochrane_Database.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (885kB) | Preview


Plasmodium vivax liver stages (hypnozoites) may cause relapses, prolonging morbidity, and impeding malaria control and elimination. The World Health Organization (WHO) recommends three schedules for primaquine: 0.25 mg/kg/day (standard), or 0.5 mg/kg/day (high standard) for 14 days, or 0.75 mg/kg once weekly for eight weeks, all of which can be difficult to complete. Since primaquine can cause haemolysis in individuals with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency, clinicians may be reluctant to prescribe primaquine without G6PD testing, and recommendations when G6PD status is unknown must be based on an assessment of the risks and benefits of prescribing primaquine. Alternative safe and efficacious regimens are needed.

Item Type: Article
Subjects: QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials
QX Parasitology > Protozoa > QX 135 Plasmodia
WC Communicable Diseases > Tropical and Parasitic Diseases > WC 750 Malaria
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):
Depositing User: Christianne Esparza
Date Deposited: 07 Oct 2020 12:09
Last Modified: 11 Nov 2020 11:47


View details

Actions (login required)

Edit Item Edit Item